ECHELON-2 Ushers In Another New Adcetris Indication For Seattle Genetics
The combination of Adcetris with chemotherapy improved progression-free and overall survival in peripheral T-cell lymphoma. Filing is expected soon, and approval will help the product reach blockbuster status.
You may also be interested in...
Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.
VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.